Latest News in Activist Investing

Times are tough, but activist investors are still finding some diamonds among the rough.

Both Carl Icahn and Eastbourne Capital have made five nominations to the board of directors of Amylin Pharmaceuticals ( AMLN) in attempts to possibly sell the company to a larger biotechnology firm.

As of their latest filings, Carl Icahn owns approximately 8.3% of Amylin, and Eastbourne Capital owns approximately 12.5%.

San Diego-based Amylin Pharmaceuticals is the maker of the diabetes drug Byetta, with a joint 50-50 partnership with Eli Lilly ( LLY), thus making Lilly the most likely candidate to buy Amylin.

To read more about this and other activist situations, visit Stockpickr.com.

Stockpickr is a wholly owned subsidiary of TheStreet.com.

More from Investing

Chart of the Day: Can Disney Catch Netflix?

Chart of the Day: Can Disney Catch Netflix?

IBM Shares Fall on Mixed Earnings Report

IBM Shares Fall on Mixed Earnings Report

The Biggest Bounces Occur in Poor Markets

The Biggest Bounces Occur in Poor Markets

Netflix Shares Spike Following Strong Earnings, Subscriber Growth Numbers

Netflix Shares Spike Following Strong Earnings, Subscriber Growth Numbers

Anticipation Is Running High for Canadian Cannabis Sales

Anticipation Is Running High for Canadian Cannabis Sales